B7-H3 Protein, Human, Recombinant (His), AF647-Labeled

1. Flow cytometric analysis of anti-B7-H3 CAR expression. 293 cells were lentivirally transduced with anti-B7-H3 CAR. Flow cytometric analysis was performed with a negative control protein and B7-H3 Protein, Human, Recombinant (His), AF647-Labeled (Cat#TMPY-07060), respectively. Non-transduced 293 cells were used as a control (left).
2. Binding activity of AF 647-conjugated B7-H3 protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and B7-H3 Protein, Human, Recombinant (His), AF647-Labeled (Cat#TMPY-07060) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).

B7-H3 Protein, Human, Recombinant (His), AF647-Labeled is expressed in HEK293 Cells. The accession number is Q5ZPR3-1.

Human

HEK293 Cells

≥ 90% as determined by SDS-PAGE.

B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy